Aligos therapeutics reports recent business progress and first quarter 2025 financial results

South san francisco, calif., may 06, 2025 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025.
ALGS Ratings Summary
ALGS Quant Ranking